Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Rating) was the recipient of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 2,830,000 shares, an increase of 25.2% from the October 31st total of 2,260,000 shares. Based on an average daily trading volume, of 475,100 shares, the days-to-cover ratio is currently 6.0 days.

Analyst Ratings Changes

Several analysts have issued reports on the company. Evercore ISI boosted their target price on Viridian Therapeutics from $40.00 to $50.00 in a research note on Monday, August 15th. SVB Leerink boosted their price objective on Viridian Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a research note on Monday, August 15th. LADENBURG THALM/SH SH upped their price target on Viridian Therapeutics from $33.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday, August 16th. B. Riley raised their price objective on shares of Viridian Therapeutics from $25.00 to $40.00 in a research report on Tuesday, August 16th. Finally, HC Wainwright began coverage on shares of Viridian Therapeutics in a research report on Thursday. They issued a "buy" rating and a $35.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $42.00.

Insider Buying and Selling at Viridian Therapeutics

In other Viridian Therapeutics news, General Counsel Lara Meisner sold 8,125 shares of the business's stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $22.05, for a total value of $179,156.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.48% of the company's stock.

Institutional Investors Weigh In On Viridian Therapeutics

Viridian Therapeutics Price Performance

Shares of VRDN stock traded up $0.72 during trading hours on Thursday, reaching $25.99. The stock had a trading volume of 9,409 shares, compared to its average volume of 430,802. Viridian Therapeutics has a 12 month low of $9.47 and a 12 month high of $27.08. The firm has a market capitalization of $739.68 million, a PE ratio of -5.99 and a beta of 0.84. The company has a current ratio of 17.35, a quick ratio of 17.35 and a debt-to-equity ratio of 0.02. The stock's fifty day simple moving average is $20.69 and its 200 day simple moving average is $17.33.

About Viridian Therapeutics

(Get Rating)

Viridian Therapeutics, Inc, a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.

Featured Articles

• Get a free copy of the StockNews.com research report on Viridian Therapeutics (VRDN)
• Are the Short Sellers Still Right About Mullen Automotive stock?
• La-Z-Boy Reclines To More Comfortable Levels
• Is The Recovery Rally Here For SoFi?
• Is Apple Going To Rally Into Year End?
• Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.